1. Home
  2. LGND vs GRFS Comparison

LGND vs GRFS Comparison

Compare LGND & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ligand Pharmaceuticals Incorporated

LGND

Ligand Pharmaceuticals Incorporated

N/A

Current Price

$316.86

Market Cap

6.0B

Sector

Health Care

ML Signal

N/A

Logo Grifols S.A.

GRFS

Grifols S.A.

N/A

Current Price

$8.70

Market Cap

5.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LGND
GRFS
Founded
1987
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
5.2B
IPO Year
1997
2008

Fundamental Metrics

Financial Performance
Metric
LGND
GRFS
Price
$316.86
$8.70
Analyst Decision
Strong Buy
Buy
Analyst Count
11
2
Target Price
★ $361.27
$10.37
AVG Volume (30 Days)
185.1K
★ 735.9K
Earning Date
10-29-2026
07-28-2022
Dividend Yield
N/A
★ 3.13%
EPS Growth
★ 2886.36
N/A
EPS
★ 0.31
N/A
Revenue
★ $141,102,000.00
N/A
Revenue This Year
$8.82
$1.89
Revenue Next Year
$31.67
$6.20
P/E Ratio
$1,019.68
★ $18.67
Revenue Growth
★ 29.48
N/A
52 Week Low
$175.89
$6.96
52 Week High
$326.63
$9.77

Technical Indicators

Market Signals
Indicator
LGND
GRFS
Relative Strength Index (RSI) 55.75 73.23
Support Level $277.97 $7.18
Resistance Level $319.83 $8.83
Average True Range (ATR) 11.45 0.25
MACD -0.28 0.07
Stochastic Oscillator 67.94 91.35

Price Performance

Historical Comparison
LGND
GRFS

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About GRFS Grifols S.A.

Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.

Share on Social Networks: